PA
ELVN icon

Profund Advisors’s Enliven Therapeutics ELVN Stock Holding History

Profund Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Sell
7,726
-525
-6% -$22.3K 0.01% 660
2026
Q1 		$323K Sell
8,251
-1,928
-19% -$53.4K 0.01% 703
2025
Q4 		$157K Buy
+10,179
New +$203K ﹤0.01% 1206

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Profund Advisors's ELVN Position: Q2 2026 in Review

Profund Advisors reduced its Enliven Therapeutics (ELVN) stake by 6.4% in Q2 2026, selling an estimated $22.3K and leaving 7,726 shares worth $392K. The position accounts for 0.01% of the portfolio, ranked #660.

Profund Advisors first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Profund Advisors held 7,726 shares of Enliven Therapeutics worth $392K as of Q2 2026.
  • Profund Advisors sold 525 Enliven Therapeutics shares in Q2 2026, an estimated $22.3K.
  • Enliven Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #660 holding.
  • Profund Advisors first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.